Adjunctive Therapies for Type 1 Diabetes

In this chapter, we review attempts to improve clinical outcomes in youth with T1D with adjunctive treatments not related to insulin. While none of these adjunctive therapies have been approved for use in patients with T1D, SGLT2 and SGLT1/2 inhibitors have been used “off-label” in adults with type 1 diabetes. The experience with these agents to date indicates that patients need to carefully monitor β-hydroxybutyrate levels to avoid the development of diabetic ketoacidosis.